The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2018 | The impact of MRD as a biomarker
Nathan Fowler, MD, of The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the use of minimal residual disease (MRD) as a biomarker for lymphoma. Speaking from the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX, Dr Fowler gives an overview of current trials looking at circulating tumor DNA show promising results as circulating tumor DNA can monitor patient’s disease and predict the likelihood of relapse before it occurs. He emphasizes that MRD markers could largely impact a patient’s course of therapy whilst acting as an alternative to scans and reducing the risk of radiation as patients go through surveillance.
